细胞与基因治疗（CGT）领域就像是一座围城，城外的人想进去，城里的人想出来。一方面，艾伯维、百时美施贵宝（BMS）等 MNC 巨头纷纷入局体内 CAR-T 疗法，礼来也在近期宣布收购一家眼科基因治疗公司 Adverum；另一方面，武田制药、诺和诺德却接连宣布彻底退出细胞疗法战场，罗氏、辉瑞、渤健等跨国巨头也在集体逃离 AAV 基因治疗赛道。这一进一退之间，CGT 领域的“冰火两重天”格局，从未如此...
Source Link细胞与基因治疗（CGT）领域就像是一座围城，城外的人想进去，城里的人想出来。一方面，艾伯维、百时美施贵宝（BMS）等 MNC 巨头纷纷入局体内 CAR-T 疗法，礼来也在近期宣布收购一家眼科基因治疗公司 Adverum；另一方面，武田制药、诺和诺德却接连宣布彻底退出细胞疗法战场，罗氏、辉瑞、渤健等跨国巨头也在集体逃离 AAV 基因治疗赛道。这一进一退之间，CGT 领域的“冰火两重天”格局，从未如此...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.